Is quantitative benefit-risk modelling of drugs desirable or possible?

@article{Phillips2011IsQB,
  title={Is quantitative benefit-risk modelling of drugs desirable or possible?},
  author={Lawrence D. Phillips and Barbara Fasolo and Nikolaos Zafiropoulos and Andrea Rose-Marie Beyer},
  journal={Drug discovery today. Technologies},
  year={2011},
  volume={8 1},
  pages={
          e1-e42
        }
}
Preliminary research results with drug regulators in several European Agencies show that quantitative models developed with groups of assessors and specialists can integrate scientific data with expert value judgements, thereby extending the capabilities of regulators, and stimulating new insights about key trade-offs. As a result, the rationale for the benefit–risk balance becomes more transparent, communicable and consistent. 
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Good decision making requires good communication.

  • Drug safety
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.

  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

Similar Papers

Loading similar papers…